HIF1A and ovarian cancer: Besides that, in ovarian cancer cells, cisplatin (CDDP) can better demonstrate its therapeutic potential when combined with NSC606985, a camptothecin analog that inhibits the accumulation of HIF-1α [65], noscapine, which results in the degradation of cobalt-stabilized HIF-1α [67], or RAD001 (everolimus), an mTOR inhibitor that suppresses the expression of HIF-1α [66].